PDCD1 and hepatocellular carcinoma: An anti-PD-1 inhibitor from China called camrelizumab (SHR-1210, Hengrui Pharmaceutical, Jiangsu Lianyungang, China) is being tested for the treatment of Hodgkin lymphoma and HCC.